Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome

Polycystic ovarian syndrome (PCOS) is the most frequent endocrine disorder affecting women of reproductive age, with a prevalence of 10 to 13%. PCOS is characterized by irregular menstrual cylcles/ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology. For infertile patients seeking ovulation induction, letrozole is the drug of first choice. For PCOS patients not seeking pregnancy, there exists a variety of treatments to alleviate symptoms. It has been demonstrated that artemisinin derivatives can promote energy expenditures and insulin sensitivity by activating thermogenic

Trial Details

NCT ID
NCT06842524
Phase
PHASE2
Sponsor
Shanghai Zhongshan Hospital
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Dihydroartemisinin
  • Placebo
Locations (sample)
  • Xiamen, Fujian, China|24.47979,118.08187
  • Xiamen, Fujian, China|24.47979,118.08187
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Wenzhou, Zhejiang, China|27.99942,120.66682

Key Eligibility Criteria

  • Women with PCOS defined as having irregular menstrual cycles and hyperandrogenism. Irregular menstrual cycles are defined as \< 21 or \> 35 days or…
  • Body Mass Index (BMI) between 18.5 and 28 kg/M2
  • Negative pregnancy test
  • No plan for pregnancy in the coming 6 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →